From existing therapies to novel targets: A current view on melanoma

Frontiers in Bioscience

Volumn 11, Issue SUPPL. 1, 2006, Pages 2081-2092

  Namkoong, Jin ^a   Martino, Jeffrey J ^a   Chen, Suzie ^a  

^a RUTGERS UNIVERSITY   (United States)

Author keywords

Cell Proliferation; Grm1; MAPK; Melanoma; Metabotropic glutamate receptor; Review

Indexed keywords

EID: 33744758305     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1951     Document Type: Review

References (97)

1. American Cancer Society: Cancer Facts and Figures 2005. American Cancer Society, Atlanta (2005)
2. MacKie, R. M.: Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol, 25, 471-5 (2000)
3. Liu, Z.-J. & M. Herlyn: Molecular biology of cutaneous melanoma. In: Cancer: Principles and Practice of Oncology. Eds: V. T. J. DeVita, S. Hellman & S. A. Rosenberg. Lippincott Williams & Wilkins, Philadelphia, PA (2005)
4. Tsao, H., M. B. Atkins & A. J. Sober: Management of cutaneous melanoma. N Engl J Med, 351, 998-1012 (2004)
5. Morton, D. L., D. R. Wen, J. H. Wong, J. S. Economou, L. A. Cagle, F. K. Storm, L. J. Foshag & A. J. Cochran: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg, 127, 392-9 (1992)
6. Macripo, G., P. Quaglino, V. Caliendo, A. M. Ronco, S. Soltani, E. Giacone, S. Pau, M. T. Fierro & M. G. Beraengo: Sentinel lymph node dissection in stage I/II melanoma patients: surgical management and clinical follow-up study. Melanoma Res, 14, S9-12 (2004)
7. National Cancer Institute: Melanoma: Clinical Trial. (2005)
8. Caraglia, M., G. Vitale, M. Marra, A. Budillon, P. Tagliaferri & A. Abbruzzese: Alpha-interferon and its effects on signalling pathways within cells. Curr Protein Pept Sci, 5, 475-85 (2004)
9. Bart, R. S., N. R. Porzio, A. W. Kopf, J. T. Vilcek, E. H. Cheng & Y. Farcet: Inhibition of growth of B16 murine malignant melanoma by exogenous interferon. Cancer Res, 40, 614-9 (1980)
10. Romerio, F. & D. Zella: MEK and ERK inhibitors enhance the anti-proliferative effect of interferon-alpha2b. Faseb J, 16, 1680-2 (2002)
11. Chawla-Sarkar, M., D. W. Leaman & E. C. Borden: Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res, 7, 1821-31 (2001)
12. Slaton, J. W., P. Perrotte, K. Inoue, C. P. Dinney & I. J. Fidler: Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res, 5, 2726-34 (1999)
13. Kefford, R. F.: Adjuvant therapy of cutaneous melanoma: the interferon debate. Ann Oncol, 14, 358-65 (2003)
14. Kirkwood, J. M., M. H. Strawderman, M. S. Ernstoff, T. J. Smith, E. C. Borden & R. H. Blum: Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol, 14, 7-17 (1996)
15. Kirkwood, J. M., J. G. Ibrahim, V. K. Sondak, J. Richards, L. E. Flaherty, M. S. Ernstoff, T. J. Smith, U. Rao, M. Steele & R. H. Blum: High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol, 18, 2444-58 (2000)
16. Kirkwood, J. M., J. Manola, J. Ibrahim, V. Sondak, M. S. Ernstoff & U. Rao: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res, 10, 1670-7 (2004)
17. Lens, M. B. & M. Dawes: Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol, 20, 1818-25 (2002)
18. Eggermont, A. M.: The role interferon-alpha in malignant melanoma remains to be defined. Eur J Cancer, 37, 2147-53 (2001)
19. Eklund, J. W. & T. M. Kuzel: A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol, 16, 542-6 (2004)
20. Atkins, M. B., J. Sparano, R. I. Fisher, G. R. Weiss, K. A. Margolin, K. I. Fink, L. Rubinstein, A. Louie, J. W. Mier, R. Gucalp & et al.: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma. J Clin Oncol, 11, 661-70 (1993)
21. Radny, P., U. M. Caroli, J. Bauer, T. Paul, C. Schlegel, T. K. Eigentler, B. Weide, M. Schwarz & C. Garbe: Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. Br J Cancer, 89, 1620-6 (2003)
22. Hauschild, A., M. Weichenthal, B. R. Balda, J. C. Becker, H. H. Wolff, W. Tilgen, K. W. Schulte, J. Ring, D. Schadendorf, S. Lischner, G. Burg & R. Dummer: Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis. J Clin Oncol, 21, 2883-8 (2003)
23. Atkins, M. B., M. T. Lotze, J. P. Dutcher, R. I. Fisher, G. Weiss, K. Margolin, J. Abrams, M. Sznol, D. Parkinson, M. Hawkins, C. Paradise, L. Kunkel & S. A. Rosenberg: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol, 17, 2105-16 (1999)
24. Thompson, J. F., R. A. Scolyer & R. F. Kefford: Cutaneous melanoma. Lancet, 365, 687-701 (2005)
25. Dudley, M. E., J. R. Wunderlich, J. C. Yang, R. M. Sherry, S. L. Topalian, N. P. Restifo, R. E. Royal, U. Kammula, D. E. White, S. A. Mavroukakis, L. J. Rogers, G. J. Gracia, S. A. Jones, D. P. Mangiameli, M. M. Pelletier, J. Gea-Banacloche, M. R. Robinson, D. M. Berman, A. C. Filie, A. Abati & S. A. Rosenberg: Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, 2346-57 (2005)
26. Eggermont, A. M. & J. M. Kirkwood: Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer, 40, 1825-36 (2004)
27. Chapman, P. B., L. H. Einhorn, M. L. Meyers, S. Saxman, A. N. Destro, K. S. Panageas, C. B. Begg, S. S. Agarwala, L. M. Schuchter, M. S. Ernstoff, A. N. Houghton & J. M. Kirkwood: Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol, 17, 2745-51 (1999)
28. Greco, O., S. D. Scott, B. Marples & G. U. Dachs: Cancer gene therapy: 'delivery, delivery, delivery'. Front Biosci, 7, d1516-24 (2002)
29. Kaiser, J.: Gene therapy. Panel urges limits on X-SCID trials. Science, 307, 1544-5 (2005)
30. Marshall, E.: Gene therapy death prompts review of adenovirus vector. Science, 286, 2244-5 (1999)
31. Zhang, L., E. Nolan, S. Kreitschitz & D. P. Rabussay: Enhanced delivery of naked DNA to the skin by non-invasive in vivo electroporation. Biochim Biophys Acta, 1572, 1-9 (2002)
32. Zhu, H., K. Reuhl, R. Botha, K. Ryan, J. Wei & S. Chen: Development of early melanocytic lesions in transgenic mice predisposed to melanoma. Pigm. Cell Res., 13, 158-164 (2000)
33. Zhu, H., K. Reuhl, X. Zhang, R. Botha, K. Ryan, J. Wei & S. Chen: Development of heritable melanoma in transgenic mice. J. Invest. Dermatol., 110, 247-252 (1998)
34. Chen, S., H. Zhu, W. J. Wetzel & M. A. Philbert: Spontaneous melanocytosis in transgenic mice. J. Invest. Dermatol., 106, 1145-1150 (1996)
35. Chen, S., L. Tiecher, D. Kazim, R. Pollack & L. Wise: Commitment of mouse fibroblasts to adipocyte differentiation by DNA transfection. Science, 244, 582-585 (1989)
36. Pollock, P. M., K. Cohen-Solal, R. Sood, J. Namkoong, J. J. Martino, A. Koganti, H. Zhu, C. Robbins, I. Makalowska, S. S. Shin, Y. Marin, K. G. Roberts, L. M. Yudt, A. Chen, J. Cheng, A. Incao, H. W. Pinkett, C. L. Graham, K. Dunn, S. M. Crespo-Carbone, K. R. Mackason, K. B. Ryan, D. Sinsimer, J. Goydos, K. R. Reuhl, M. Eckhaus, P. S. Meltzer, W. J. Pavan, J. M. Trent & S. Chen: Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet, 34, 108-12 (2003)
37. Marin, Y. E. & S. Chen: Involvement of metabotropic glutamate receptor 1, a G protein coupled receptor, in melanoma development. J Mol Med, 82, 735-49 (2004)
38. Lahav, R., G. Heffher & P. H. Patterson: An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Natl Acad Sci U S A, 96, 11496-500 (1999)
39. Ferraguti, F., B. Baldani-Guerra, M. Corsi, S. Nakanishi & C. Corti: Activation of the extracellular signal-regulated kinase 2 by metabotropic glutamate receptors. Eur J Neurosci, 11, 2073-2082 (1999)
40. Thandi, S., J. L. Blank & R. A. Challiss: Group-I metabotropic glutamate receptors, mGlu1a and mGlu5a, couple to extracellular signal-regulated kinase (ERK) activation via distinct, but overlapping, signalling pathways. J Neurochem, 83, 1139-53 (2002)
41. Satyamoorthy, K., G. Li, M. R. Gerrero, M. S. Brose, P. Volpe, B. L. Weber, P. Van Belle, D. E. Elder & M. Herlyn: Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res, 63, 756-9 (2003)
42. Marin, Y. E., J. Namkoong, S. S. Shin, J. Raines, K. Degenhardt, E. White & S. Chen: Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology, 49 Suppl, 70-9 (2005)
43. Francesconi, A. & R. Duvoisin: Role of the second and third intracellular loops of metabotropic glutamate receptors in mediatic dual signal transduction activation. J. biol. Chem., 273, 5615-5624 (1998)
44. Clark, B. P., Baker, S. Richard, Goldsworthy, John, Harris, John R., Kingston, Ann E.: (+)-2-Methyl-4-Carboxylphenylglycine (LY367385) Selectively Antagonises Metabotropic Glutamate mGLuR1 Receptors. Bioorganic & Medicinal Chemistry Letters, 1, 2777-2780 (1997)
45. Gasparini, F., P. Floersheim, P. J. Flor, M. Heinrich, W. Inderbitzin, D. Ott, A. Pagano, C. Stierlin, N. Stoehr, I. Vranesic & R. Kuhn: Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco, 56, 95-9 (2001)
46. Carroll, F. Y., A. Stolle, P. M. Beart, A. Voerste, I. Brabet, F. Mauler, C. Joly, H. Antonicek, J. Bockaert, T. Muller, J. P. Pin & L. Prezeau: BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol, 59, 965-73. (2001)
47. Brakeman, P. R., A. A. Lanahan, R. O'Brien, K. Roche, C. A. Barnes, R. L. Huganir & P. F. Worley: Homer: a protein that selectively binds metabotropic glutamate receptors. Nature, 386, 284-8 (1997)
48. Tu, J. C., B. Xiao, J. P. Yuan, A. A. Lanahan, K. Leoffert, M. Li, D. J. Linden & P. F. Worley: Homer binds a novel proline-rich motif and links group 1 metabotropic glutamate receptors with IP3 receptors. Neuron, 21, 717-26 (1998)
49. Prezeau, L., J. Gomeza, S. Ahern, S. Mary, T. Galvez, J. Bockaert & J. P. Pin: Changes in the carboxyl-terminal domain of metabotropic glutamate receptor 1 by alternative splicing generate receptors with differing agonist-independent activity. Mol Pharmacol, 49, 422-9. (1996)
50. Ango, F., J. P. Pin, J. C. Tu, B. Xiao, P. F. Worley, J. Bockaert & L. Fagni: Dendritic and axonal targeting of type 5 metabotropic glutamate receptor is regulated by homerl proteins and neuronal excitation. J Neurosci, 20, 8710-6 (2000)
51. Ango, F., L. Prezeau, T. Muller, J. C. Tu, B. Xiao, P. F. Worley, J. P. Pin, J. Bockaert & L. Fagni: Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer. Nature, 411, 962-5. (2001)
52. Smalley, K. S. & T. G. Eisen: Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int J Cancer, 105, 165-75 (2003)
53. Adjei, A. A.: Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst, 93, 1062-74 (2001)
54. Marshall, C. J.: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell, 80, 179-85 (1995)
55. van Elsas, A., S. F. Zerp, S. van der Flier, K. M. Kruse, C. Aarnoudse, N. K. Hayward, D. J. Ruiter & P. I. Schrier: Relevance of ultraviolet-induced N-ras oncogene point mutations in development of primary human cutaneous melanoma. Am J Pathol, 149, 883-93 (1996)
56. Eastman, A.: Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2, 275-80 (1990)
57. Halaschek-Wiener, J., Y. Kloog, V. Wacheck & B. Jansen: Farnesyl thiosalicylic acid chemosensitizes human melanoma in vivo. J Invest Dermatol, 120, 109-15 (2003)
58. Smalley, K. S. & T. G. Eisen: Farnesyl thiosalicylic acid inhibits the growth of melanoma cells through a combination of cytostatic and pro-apoptotic effects. Int J Cancer, 98, 514-22. (2002)
59. Eskandarpour, M., S. Kiaii, C. Zhu, J. Castro, A. J. Sakko & J. Hansson: Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer (2005)
60. Storm, S. M., J. L. Cleveland & U. R. Rapp: Expression of raf family proto-oncogenes in normal mouse tissues. Oncogene, 5, 345-51 (1990)
61. Schaap, D., J. van der Wal, L. R. Howe, C. J. Marshall & W. J. van Blitterswijk: A dominant-negative mutant of raf blocks mitogen-activated protein kinase activation by growth factors and oncogenic p21ras. J Biol Chem, 268, 20232-6 (1993)
62. Wellbrock, C., M. Karasarides & R. Marais: The RAF proteins take centre stage. Nat Rev Mol Cell Biol, 5, 875-85 (2004)
63. Karasarides, M., A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanion, F. Friedlos, L. Ogilvie, D. Hedley, J. Martin, C. J. Marshall, C. J. Springer & R. Marais: B-RAF is a therapeutic target in melanoma. Oncogene, 23, 6292-8 (2004)
64. Wellbrock, C., L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer & R. Marais: V599EB-RAF is an oncogene in melanocytes. Cancer Res, 64, 2338-42 (2004)
65. Davies, H., G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton & P. A. Futreal: Mutations of the BRAF gene in human cancer. Nature, 417, 949-954 (2002)
66. Pollock, P. M., U. L. Harper, K. S. Hansen, L. M. Yudt, M. Stark, C. M. Robbins, T. Y. Moses, G. Hosteller, U. Wagner, J. Kakareka, G. Salem, T. Pohida, P. Heenan, P. Duray, O. Kallioniemi, N. K. Hayward, J. M. Trent & P. S. Meltzer: High frequency of BRAF mutations in nevi. Nat Genet, 33, 19-20 (2003)
67. Dong, J., R. G. Phelps, R. Qiao, S. Yao, O. Benard, Z. Ronai & S. A. Aaronson: BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res, 63, 3883-5 (2003)
68. Goydos, J. S., B. Mann, H. J. Kim, E. M. Gabriel, J. Alsina, F. J. Germino, W. Shih & D. H. Gorski: Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg, 200, 362-70 (2005)
69. Halaban, R., S. Ghosh, P. Duray, J. M. Kirkwood & A. B. Lerner: Human melanocytes cultured from nevi and melanomas. J Invest Dermatol, 87, 95-101 (1986)
70. Hingorani, S. R., M. A. Jacobetz, G. P. Robertson, M. Herlyn & D. A. Tuveson: Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res, 63, 5198-202 (2003)
71. Bhatt, K. V., L. S. Spofford, G. Aram, M. McMullen, K. Pumiglia & A. E. Aplin: Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene, 24, 3459-71 (2005)
72. Sumimoto, H., M. Miyagishi, H. Miyoshi, S. Yamagata, A. Shimizu, K. Taira & Y. Kawakami: Inhibition of growth and invasive ability of melanoma by inactivation of mutated BRAF with lentivirus-mediated RNA interference. Oncogene, 23, 6031-9 (2004)
73. Danson, S. & P. Lorigan: Improving outcomes in advanced malignant melanoma: update on systemic therapy. Drugs, 65, 733-43 (2005)
74. Stebbins, C. E., A. A. Russo, C. Schneider, N. Rosen, F. U. Hartl & N. P. Pavletich: Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. Cell, 89, 239-50 (1997)
75. Workman, P.: Overview: translating Hsp90 biology into Hsp90 drugs. Curr Cancer Drug Targets, 3, 297-300 (2003)
76. Ikenoue, T., Y. Hikiba, F. Kanai, Y. Tanaka, J. Imamura, T. Imamura, M. Ohta, H. Ijichi, K. Tateishi, T. Kawakami, J. Aragaki, M. Matsumura, T. Kawabe & M. Omata: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res, 63, 8132-7 (2003)
77. Burger, A. M., H. H. Fiebig, S. F. Stinson & E. A. Sausville: 17-(Allylamino)-17-demethoxygeldanamycin activity in human melanoma models. Anticancer Drugs, 15, 377-87 (2004)
78. Ge, X., Y. M. Fu & G. G. Meadows: U0126, a mitogen-activated protein kinase kinase inhibitor, inhibits the invasion of human A375 melanoma cells. Cancer Lett, 179, 133-40 (2002)
79. Huntington, J. T., J. M. Shields, C. J. Der, C. A. Wyatt, U. Benbow, C. L. Slingluff, Jr. & C. E. Brinckerhoff: Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J Biol Chem, 279, 33168-76 (2004)
80. Favata, M. F., K. Y. Horiuchi, E. J. Manos, A. J. Daulerio, D. A. Stradley, W. S. Feeser, D. E. Van Dyk, W. J. Pitts, R. A. Earl, F. Hobbs, R. A. Copeland, R. L. Magolda, P. A. Scherle & J. M. Trzaskos: Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem, 273, 18623-32 (1998)
81. Dudley, D. T., L. Pang, S. J. Decker, A. J. Bridges & A. R. Saltiel: A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A, 92, 7686-9 (1995)
82. Mandic, A., K. Viktorsson, T. Heiden, J. Hansson & M. C. Shoshan: The MEK1 inhibitor PD98059 sensitizes C8161 melanoma cells to cisplatin-induced apoptosis. Melanoma Res, 11, 11-9 (2001)
83. Goodall, J., C. Wellbrock, T. J. Dexter, K. Roberts, R. Marais & C. R. Coding: The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol Cell Biol, 24, 2923-31 (2004)
84. Jean, D., C. Tellez, S. Huang, D. W. Davis, C. J. Bruns, D. J. McConkey, S. H. Hinrichs & M. Bar-Eli: Inhibition of tumor growth and metastasis of human melanoma by intracellular anti-ATF-1 single chain Fv fragment. Oncogene, 19, 2721-30 (2000)
85. Robertson, G. P.: Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev, 24, 273-85 (2005)
86. Dai, D. L., M. Martinka & G. Li: Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J Clin Oncol, 23, 1473-82 (2005)
87. Stahl, J. M., A. Sharma, M. Cheung, M. Zimmerman, J. Q. Cheng, M. W. Bosenberg, M. Kester, L. Sandirasegarane & G. P. Robertson: Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res, 64, 7002-10 (2004)
88. Nakanishi, C. & M. Toi: Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer, 5, 297-309 (2005)
89. Amiri, K. I. & A. Richmond: Role of nuclear factor-kappa B in melanoma. Cancer Metastasis Rev, 24, 301-13 (2005)
90. Amiri, K. I., L. W. Horton, B. J. LaFleur, J. A. Sosman & A. Richmond: Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res, 64, 4912-8 (2004)
91. Soengas, M. S. & S. W. Lowe: Apoptosis and melanoma chemoresistance. Oncogene, 22, 3138-51 (2003)
92. Chawla-Sarkar, M., S. I. Bae, F. J. Reu, B. S. Jacobs, D. J. Lindner & E. C. Borden: Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ, 11, 915-23 (2004)
93. Heere-Ress, E., C. Thallinger, T. Lucas, H. Schlagbauer-Wadl, V. Wacheck, B. P. Monia, K. Wolff, H. Pehamberger & B. Jansen: Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer, 99, 29-34 (2002)
94. Kim, R., M. Emi, K. Tanabe & T. Toge: Therapeutic potential of antisense Bcl-2 as a chemosensitizer for cancer therapy. Cancer, 101, 2491-502 (2004)
95. Jansen, B., V. Wacheck, E. Heere-Ress, H. Schlagbauer-Wadl, C. Hoeller, T. Lucas, M. Hoermann, U, Hollenstein, K. Wolff & H. Pehamberger: Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet, 356, 1728-33 (2000)
96. Chang, H. J., B. C. Yoo, S. B. Lim, S. Y. Jeong, W. H. Kim & J. G. Park: Metabotropic glutamate receptor 4 expression in colorectal carcinoma and its prognostic significance. Clin Cancer Res, 11, 3288-95 (2005)
97. Rzeski, W., L. Turski & C. Ikonomidou: Glutamate antagonists limit tumor growth. Proc. Natl. Acad. Sci. USA, 98, 6372-6377 (2001)